This article is more than 5 years old. Information may no longer be current.

Aerie Pharmaceuticals reports net loss of $23.2 million in second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aerie Pharmaceuticals reported a net loss attributable to common stockholders of $23.2 million, or $0.87 per share, in the second quarter compared with a net loss of $18.8 million, or $0.73 per share, in the same period last year, according to a press release.

The net loss was attributed to $13.3 million in research and development expenses and $9.4 million in general and administrative expenses. Higher operating expenses compared with last year included expansion of the company’s employee base to support growth of operations.

Aerie expects to file a new drug application for Rhopressa (netarsudil ophthalmic solution 0.02%) for the treatment of patients with glaucoma or ocular hypertension in the third quarter. In addition, 90-day interim topline efficacy readout from Mercury 1, the first phase 3 clinical trial for Roclatan (netarsudil 0.02%/latanoprost ophthalmic solution 0.005%), is expected in September, according to the release.